Oppenheimer & Co. Inc. grew its position in DermTech, Inc. (NASDAQ:DMTK – Free Report) by 253.0% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 35,295 shares of the company’s stock after buying an additional 25,295 shares during the period. Oppenheimer & Co. Inc. owned 0.11% of DermTech worth $130,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of DMTK. Gateway Wealth Partners LLC purchased a new position in shares of DermTech in the 1st quarter valued at approximately $273,000. White Pine Capital LLC raised its position in shares of DermTech by 21.9% in the 1st quarter. White Pine Capital LLC now owns 259,178 shares of the company’s stock valued at $954,000 after purchasing an additional 46,504 shares during the last quarter. Triatomic Management LP raised its position in shares of DermTech by 21.6% in the 1st quarter. Triatomic Management LP now owns 154,652 shares of the company’s stock valued at $569,000 after purchasing an additional 27,444 shares during the last quarter. Kovack Advisors Inc. purchased a new position in shares of DermTech in the 1st quarter valued at approximately $43,000. Finally, Trellus Management Company LLC purchased a new position in shares of DermTech in the 1st quarter valued at approximately $137,000. 27.81% of the stock is currently owned by institutional investors.
DermTech Trading Down 4.2 %
DMTK opened at $2.30 on Friday. DermTech, Inc. has a 12-month low of $1.55 and a 12-month high of $6.44. The firm has a market capitalization of $77.51 million, a PE ratio of -0.59 and a beta of 2.18. The firm has a 50 day moving average of $2.77 and a two-hundred day moving average of $3.18.
Analyst Upgrades and Downgrades
Separately, BTIG Research decreased their price objective on shares of DermTech from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, August 7th.
DermTech Company Profile
DermTech, Inc, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers.
- Five stocks we like better than DermTech
- How to Invest in Artificial Intelligence
- 3 Takeaways from the August Inflation Report
- Dividend Capture Strategy: What You Need to Know
- On Fire: 5 Best Artificial Intelligence Penny Stocks
- How to Invest in the Entertainment Industry
- 6 Cybersecurity Stocks: Which is the Best to Buy?
Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.